<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Wilcox | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/ashdrain0/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/ashdrain0/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Wilcox.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">02ff850c0c29a41b7892f79f0f978eed</guid>
				<title>Wilcox posted an update: immunization of mice with mentioned antigens especially a [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41123/</link>
				<pubDate>Fri, 07 Feb 2025 11:28:31 -0800</pubDate>

									<content:encoded><![CDATA[<p>immunization of mice with mentioned antigens especially a mixture of them, could eliminate the biofilm formation process in </p>
<p> . Hopefully, this study corresponds to the suggestion that the immunization of mice with PIA and rSesC candidate vaccines could protect against </p>
<p> infection.</p>
<p>immunization of mice with mentioned antigens especially a&hellip;<span class="activity-read-more" id="activity-read-more-41123"><a href="http://www.nationalboardinstitute.com/activity/p/41123/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">b42e1597baed2caba632d20c317eb3ef</guid>
				<title>Wilcox posted an update: Here we describe six approaches that capture three core [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/40068/</link>
				<pubDate>Thu, 06 Feb 2025 12:50:10 -0800</pubDate>

									<content:encoded><![CDATA[<p>Here we describe six approaches that capture three core focus areas for lipidomics (1) lipidome annotation including a resolvable database identifier, (2) interpretation via pathway- and enrichment-based methods, and (3) understanding complex interactions to emphasize specific steps in the analytical process and highlight challenges in analyses&hellip;<span class="activity-read-more" id="activity-read-more-40068"><a href="http://www.nationalboardinstitute.com/activity/p/40068/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">8be8a552f49d62d5876563b1e220e681</guid>
				<title>Wilcox posted an update: Herein, our group proposes circSNX6 as key regulator for [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/39175/</link>
				<pubDate>Wed, 05 Feb 2025 11:18:55 -0800</pubDate>

									<content:encoded><![CDATA[<p>Herein, our group proposes circSNX6 as key regulator for drug resistance of NSCLC. The findings provide solid groundings for understanding of NSCLC pathogenesis and development of therapeutics.Enhancer of zeste homolog 2 (EZH2) is the catalytic core of polycomb repressive complex 2 (PRC2), which primarily methylates lysine 27 on histone H3&hellip;<span class="activity-read-more" id="activity-read-more-39175"><a href="http://www.nationalboardinstitute.com/activity/p/39175/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">eebba601b33fe49575b465a6f747d3dd</guid>
				<title>Wilcox posted an update: Low barrier addiction clinics increase access to medications [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/37594/</link>
				<pubDate>Mon, 03 Feb 2025 11:30:40 -0800</pubDate>

									<content:encoded><![CDATA[<p>Low barrier addiction clinics increase access to medications to treat substance use disorders, while emphasizing harm reduction. The Harm Reduction and BRidges to Care (HRBR) Clinic is an on demand, low barrier addiction clinic that opened in October 2019. In the first three months of operation (November through January 2020), HRBR saw steadily&hellip;<span class="activity-read-more" id="activity-read-more-37594"><a href="http://www.nationalboardinstitute.com/activity/p/37594/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d08b4e04d6a220f3730a117c439ab349</guid>
				<title>Wilcox posted an update: Out of nine different 7-deaza-adenosine diarylethenes, we [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/29282/</link>
				<pubDate>Tue, 28 Jan 2025 13:01:17 -0800</pubDate>

									<content:encoded><![CDATA[<p>Out of nine different 7-deaza-adenosine diarylethenes, we identified a high-performance photoswitch, suitable for the synthesis of photochromic DNA. By using solid phase synthesis, a photoresponsive T7 promotor was generated which allowed reversibly modulating the rate of enzymatic RNA synthesis in vitro.Highly active, cost-effective and durable&hellip;<span class="activity-read-more" id="activity-read-more-29282"><a href="http://www.nationalboardinstitute.com/activity/p/29282/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ffe62534626d3f24cd2fe57fc24932a9</guid>
				<title>Wilcox became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/29174/</link>
				<pubDate>Tue, 28 Jan 2025 12:54:53 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>